A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 33
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : MPS II
Long Form : mucopolysaccharidosis II
No. Year Title Co-occurring Abbreviation
2022 Clinical Characteristics and Healthcare Resource Utilization for Patients with Mucopolysaccharidosis II (MPS II) in the United States: A Retrospective Chart Review. ---
2022 Dose-dependent effects of a brain-penetrating iduronate-2-sulfatase on neurobehavioral impairments in mucopolysaccharidosis II mice. CSF, HS
2022 Impact of the Timing of Enzyme Replacement Therapy Initiation and Cognitive Impairment Status on Outcomes for Patients with Mucopolysaccharidosis II (MPS II) in the United States: A Retrospective Chart Review. CI, ERT, HRU
2022 Long-term open-label phase I/II extension study of intrathecal idursulfase-IT in the treatment of neuronopathic mucopolysaccharidosis II. AEs, i.t
2022 Newborn Screening Program for Mucopolysaccharidosis Type II and Long-Term Follow-Up of the Screen-Positive Subjects in Taiwan. ERT, GAGs, HSCT, IDS
2021 Analysis of cognitive ability and adaptive behavior assessment tools used in an observational study of patients with mucopolysaccharidosis II. ABC, DAS-II, GCA, HS-FOCUS, SD, VABS-II
2021 Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice. BBB, CSF, HS, IDS
2021 Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS). ERT, HOS
2021 Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II. CSF, HS
10  2021 MUCOPOLYSACCHARIDOSIS II (MPS II) IN A FREE-LIVING KAKA (NESTOR MERIDIONALIS) IN NEW ZEALAND. MPS
11  2019 Cochlear Implantation via the Transmeatal Approach in an Adolescent with Hunter Syndrome-Type II Mucopolysaccharidosis. CI, SNHL
12  2019 Identification of the iduronate-2-sulfatase proteome in wild-type mouse brain. CNS, IDS
13  2019 Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial. BBB, DS, HS, IDS
14  2019 Modelling the neuropathology of lysosomal storage disorders through disease-specific human induced pluripotent stem cells. IDS, LMP, LSD, NPCs
15  2019 Ten years of enzyme replacement therapy in paediatric onset mucopolysaccharidosis II in England. ERT
16  2018 A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II. BBB, GAGs, hIDS, hTfR, IDS
17  2018 Oral and craniofacial manifestations in a Hunter syndrome patient with hematopoietic stem cell transplantation: A case report. HSCT
18  2018 The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology. CSF, ERT, GAG, HS, i.c.v, IDS-beta
19  2017 Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients. HOS, irAEs, uGAGs
20  2017 Hematopoietic Stem Cell Transplantation for Patients with Mucopolysaccharidosis II. ERT, GAG, HSCT, MRI
21  2015 Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study. CGI-I, ERT, PGI-I, QoL
22  2014 Brazilian reference values for MPS II screening in dried blood spots--a fluorimetric assay. DBS, IDS
23  2014 Growth charts for patients with Hunter syndrome. ---
24  2014 Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series. ERT
25  2012 Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls. ---
26  2012 Hunter syndrome (Muccopolysaccharridosis Type II) in Macedonia and Bulgaria. IDS
27  2011 Changes in glycogen and glycosaminoglycan levels in hepatocytes of iduronate-2-sulfatase knockout mice before and after recombinant iduronate-2-sulfatase supplementation. ERT, GAG, IdS, KO
28  2011 Long-term enzyme replacement therapy in a severe case of mucopolysaccharidosis type II (Hunter syndrome). ERT, GAGs
29  2010 Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review. LD
30  2009 [Difficult tracheal intubation using airway scope in a pediatric patient with Hunter syndrome]. AWS, FOB
31  2006 A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). ---
32  2006 Multiple cryptic splice sites can be activated by IDS point mutations generating misspliced transcripts. IDS
33  1984 Hearing loss in Hunter's syndrome--mucopolysaccharidosis II. ---